Mitchell Chace B, Simmons Joe, Hodo Carolyn L, Neal Sarah J, Chitta Sriram, Vo Clementine, Bakshi Kanwarpal, Juliani Julie, Fenske Julie, Cleveland David C, Cleveland John D
Division of Cardiac Surgery, Department of Surgery, Children's Hospital Los Angeles, Los Angeles, CA.
Michale E. Keeling Center for Comparative Medicine, MD Anderson Cancer Center, Bastrop, TX.
J Heart Lung Transplant. 2025 Apr;44(4):503-510. doi: 10.1016/j.healun.2024.12.011. Epub 2025 Jan 6.
Genetically engineered porcine hearts may have an application for infants in need of a bridge to cardiac allotransplantation. The current animal model that resulted in 2 human applications has been validated in adult non-human primates only. We sought to create an infant animal model of life sustaining cardiac xenotransplantation to understand limitations specific to this age group.
We performed 11 orthotopic cardiac xenotransplants from genetically modified infantile pigs into size-matched baboons (Papio spp). Porcine grafts were preserved using a modified Del Nido solution. Protocolized post-operative care and outcomes were tracked with invasive monitoring, echocardiogram, and serial chemistries (including a 7-cytokine panel).
Mean ischemic time was 52.1 +/- 13.9 min. All porcine hearts separated from bypass in normal sinus rhythm with normal systolic function documented by echocardiogram at chest closure and again at 24 h. In the first 48 post-operative hours, mean vasoactive inotropic score for the recipients was 9.6 +/- 3.5. Survival >3months was achieved in 6 animals. Five animals succumbed early (<7days) either due to errors in care (n=2) or pulmonary complications (n=3) confirmed on chest radiograph and necropsy. Cytokine levels objectively increased following xenograft implant but were not significantly different between survivors and non-survivors.
In a non-human primate model of infant orthotopic cardiac xenotransplantation, cardiac function does not hinder early peri-operative survival. Instead, pulmonary edema and pleural effusions in the setting of systemic inflammation preclude clinical progression. Targeted therapies are necessary to encourage prolonged survival.
基因工程猪心脏可能对需要心脏同种异体移植过渡的婴儿有应用价值。目前导致2例人体应用的动物模型仅在成年非人灵长类动物中得到验证。我们试图建立一个维持生命的心脏异种移植婴儿动物模型,以了解该年龄组特有的局限性。
我们将11例基因改造的幼年猪的心脏原位异种移植到大小匹配的狒狒(狒狒属)体内。猪移植物用改良的Del Nido溶液保存。通过有创监测、超声心动图和系列化学检查(包括7种细胞因子检测)追踪术后标准化护理及结果。
平均缺血时间为52.1±13.9分钟。所有猪心脏在体外循环结束时以正常窦性心律分离,超声心动图显示收缩功能正常,术后24小时再次检查亦如此。术后最初48小时内,受体的平均血管活性药物评分是9.6±3.5。6只动物存活超过3个月。5只动物早期死亡(<7天),其中2只因护理失误,3只因胸部X光和尸检证实的肺部并发症。异种移植植入后细胞因子水平客观上升,但存活者与非存活者之间无显著差异。
在婴儿原位心脏异种移植的非人灵长类动物模型中,心脏功能并不妨碍围手术期早期存活。相反,全身炎症背景下的肺水肿和胸腔积液阻碍了临床进展。需要有针对性的治疗来延长生存期。